Meglumine antimoniate description: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Description== | |||
Pentavalent antimony compounds with leishmanicidal activity, but which are not effective against free flagellated forms in vitro. It is uncertain whether they have selective activity against intracellular forms, or whether small amounts are converted intracellularly into a potent trivalent inhibitor of the parasite’s glycolytic enzymes. | |||
Since they are poorly absorbed and highly irritant to the gastrointestinal tract they must be administered parenterally or by local injection. Over 80% of the dose is excreted unchanged in the urine within 6 hours.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:39, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Description
Pentavalent antimony compounds with leishmanicidal activity, but which are not effective against free flagellated forms in vitro. It is uncertain whether they have selective activity against intracellular forms, or whether small amounts are converted intracellularly into a potent trivalent inhibitor of the parasite’s glycolytic enzymes.
Since they are poorly absorbed and highly irritant to the gastrointestinal tract they must be administered parenterally or by local injection. Over 80% of the dose is excreted unchanged in the urine within 6 hours.[1]
References
Adapted from the FDA Package Insert.